# US 11,992,487 B2 · Quinolines that modulate SERCA and their use for treating disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,992,487 B2
- Document ID: US11992487B2
- Status: Granted
- Kind: B2
- Application number: 18/229,474
- Filed: 2023-08-02
- Published: 2024-01-18
- Granted: 2024-05-28
- Earliest claimed: 2020-07-20
- Assignees: Neurodon Corporation
- Applicants: Neurodon Corporation
- Inventors: Russell Dahl
- Web page: https://patentgrep.com/patent/US11992487B2

## CPC

- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- C07D 215/40: attached in position 8
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.

## Claims

### Claim 1

A pharmaceutical composition comprising:
i) a compound of the following structural formula:
or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and
ii) a pharmaceutically acceptable carrier, excipient or diluent.